Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Effect of Tezepelumab on the Immune Response to Influenza Vaccination in Participants With Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Documented physician-diagnosed asthma for at least 12 months prior to Visit 1.~* Morning pre-bronchodilator FEV1 (Forced expiratory volume) of \> 50% predicted normal value at Visit 1 or Visit 2.~* Body weight ≥ 40 kg.~* For women of childbearing potential, a negative urine pregnancy test is required prior to administration of study intervention at Visit 3.~* Must have 'not well-controlled' asthma.~Exclusion Criteria:~* Clinically important pulmonary disease other than asthma.~* Any disorder, including, but not limited to, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, hematological, psychiatric, or major physical impairment.~* Life-threatening asthma~* History of cancer.~* Allergy to eggs, if egg based influenza vaccine will be administered.~* History of anaphylaxis to any biologic therapy.~* Current smokers or participants with smoking history ≥ 10 pack-years and participants using vaping products, including electronic cigarettes. Former smokers with a smoking history of \< 10 pack-years and users of vaping or e-cigarette products must have stopped for at least 6 months prior to Visit 1 to be eligible.~* History of alcohol or drug abuse within 12 months prior to the date of informed consent.~* Major surgery within 8 weeks prior to Visit 1 or planned surgical procedures during the conduct of the study.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Tezepelumab (Type: EXPERIMENTAL): Participants will be randomized to receive tezepelumab 210 mg administered at Weeks 0, 4, 8 and 12. Participants will also receive a single dose of inactivated quadrivalent seasonal influenza vaccine intramuscularly at Week 12, prior to the fourth dose of study intervention.
- Placebo to Tezepelumab (Type: PLACEBO_COMPARATOR): Participants will be randomized to receive placebo SC Q4W, administered at Weeks 0, 4, 8 and 12. Participants will also receive a single dose of inactivated quadrivalent seasonal influenza vaccine intramuscularly at Week 12, prior to the fourth dose of study intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).